RESUMO
A precise description of neutrino-nucleus reactions will play a key role in addressing fundamental questions such as the leptonic CP violation and the neutrino mass hierarchy through analyzing data from next-generation neutrino oscillation experiments. The neutrino energy relevant to the neutrino-nucleus reactions spans a broad range and, accordingly, the dominant reaction mechanism varies across the energy region from quasi-elastic scattering through nucleon resonance excitations to deep inelastic scattering. This corresponds to transitions of the effective degree of freedom for theoretical description from nucleons through meson-baryon to quarks. The main purpose of this review is to report our recent efforts towards a unified description of the neutrino-nucleus reactions over the wide energy range; recent overall progress in the field is also sketched. Starting with an overview of the current status of neutrino-nucleus scattering experiments, we formulate the cross section to be commonly used for the reactions over all the energy regions. A description of the neutrino-nucleon reactions follows and, in particular, a dynamical coupled-channels model for meson productions in and beyond the [Formula: see text](1232) region is discussed in detail. We then discuss the neutrino-nucleus reactions, putting emphasis on our theoretical approaches. We start the discussion with electroweak processes in few-nucleon systems studied with the correlated Gaussian method. Then we describe quasi-elastic scattering with nuclear spectral functions, and meson productions with a [Formula: see text]-hole model. Nuclear modifications of the parton distribution functions determined through a global analysis are also discussed. Finally, we discuss issues to be addressed for future developments.
RESUMO
We show that two almost degenerate poles near the piDelta threshold and the next higher mass pole in the P11 partial wave of piN scattering evolve from a single bare state through its coupling with piN, etaN, and pipiN reaction channels. This finding provides new information on understanding the dynamical origins of the Roper N{*}(1440) and N{*}(1710) resonances listed by Particle Data Group. Our results for the resonance poles in other piN partial waves are also presented.
RESUMO
Previous studies have shown that B-Myb, a conserved member of the Myb transcription factor family, is a potent activator of the promoter of the human HSP70 gene but does not activate promoters containing Myb binding sites. We have now investigated the transactivation properties of B-Myb in more detail. We here report that B-Myb activates the HSP70 promoter by a novel mechanism which involves the heat shock element (HSE). Deletion analysis of B-Myb shows that a specific domain in the center of B-Myb, but not the DNA-binding domain is required for HSE-dependent transactivation. We also show that deletion of the C-terminal domain of B-Myb does not affect HSE-dependent transactivation but allows the protein to activate a promoter containing Myb binding sites. This suggests that the ability to activate Myb binding site containing promoters is repressed in the context of full length B-Myb and that HSE dependent and Myb binding site dependent transactivation are distinct functions of B-Myb. Finally, we report that cyclin D1 like B-Myb strongly activates the HSP70 promoter via the HSE. HSE-dependent transactivation is a novel activity of cyclin D1 and appears to be independent of the phosphorylation of the Rb protein. Our results reveal an interesting and unexpected connection between HSE-dependent gene activation and proteins expressed during the G1/S-transition of the cell cycle.
Assuntos
Ciclinas/fisiologia , Proteínas de Ligação a DNA/fisiologia , Proteínas de Choque Térmico HSP70/fisiologia , Proteínas Oncogênicas/fisiologia , Regiões Promotoras Genéticas/fisiologia , Fatores de Transcrição/fisiologia , Ativação Transcricional/fisiologia , Sítios de Ligação , Ciclina D1 , Fase G1/fisiologia , Humanos , Fase S/fisiologiaRESUMO
The myb gene family consists of three members, the c-myb proto-oncogene and two myb-related genes (A-myb and B-myb), all of which encode nuclear DNA-binding proteins. Unlike c-myb, which plays a critical role in hematopoietic cells, B-myb is expressed in a large spectrum of hematopoietic as well as non-hematopoietic cells and has been implicated in the control of cell proliferation. The isolation of B-myb cDNA clones from several species has shown that B-myb shares limited homology to the so-called exon 9A of the c-myb gene. This exon is involved in differential splicing as only a subfraction of c-myb mRNA contains exon 9A sequences. The presence in the B-myb cDNA of a sequence related to the exon 9A of c-myb has prompted us to investigate whether B-myb mRNA is also spliced differentially. We here show that B-myb mRNAs containing or lacking exon 9A related sequences are present in many cell types. In contrast to c-myb, where RNA containing the exon 9A constitutes only a minor mRNA fraction, B-myb RNA containing the exon 9A related sequences is the major mRNA form. The proteins encoded by the two B-myb mRNA species are unable to activate promoters to which they bind. Curiously, both B-myb proteins differ in their ability to activate the HSP70 promoter by a myb binding-site independent mechanism; B-myb protein containing exon 9A related aminoacid sequences activates the HSP70 promoter much more potently than the B-myb protein which lacks these sequences. Our results suggest that differential splicing may be a general feature of the members of the myb family and provide first evidence for functional differences of the splice variants.
Assuntos
Oncogenes , Splicing de RNA , Sequência de Aminoácidos , Animais , Sequência de Bases , Linhagem Celular , Proteínas de Choque Térmico HSP70/genética , Camundongos , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Regiões Promotoras Genéticas , RNA Mensageiro/análiseRESUMO
B-myb is a member of the myb family of nuclear sequence-specific DNA-binding proteins which has been highly conserved among vertebrates. B-myb has been implicated in the control of cell proliferation, particularly at the G1/S transition of the cell cycle. So far, most of the work on B-myb has been performed in immortalized cell lines. Since these cells might show aberrant behavior of genes involved in proliferation control we have begun to investigate the role of B-myb in normal cells. As a first step, we have studied the expression of B-myb during mouse development. Here, we show the B-myb is expressed at similar levels during all stages of embryogenesis. In situ hybridization reveals a tight linkage between B-myb expression and proliferative activity (as assessed by the expression of the S-phase specific histone H4 gene) in most tissues and throughout embryonic development. However, B-myb and histone H4 expression are uncoupled during spermatogenesis in the adult mouse. Histone H4 is expressed at high levels in the early spermatogenic progenitor cells but not in successive stages of sperm cell development. By contrast, the highest levels of B-myb expression are found during the intermediate stages of spermatogenesis. Furthermore, we have found that B-myb mRNA isolated from the testis differs in size from that of other tissues. The data presented here strongly support the notion that B-myb plays a general role during proliferation of most cells. Furthermore, our results raise the possibility that the function of B-myb in cells undergoing meiosis may be different from its role in cells dividing mitotically.
Assuntos
Proteínas de Ciclo Celular , Proteínas de Ligação a DNA/genética , Regulação da Expressão Gênica no Desenvolvimento , Transativadores , Fatores de Transcrição/genética , Animais , Sequência de Bases , Northern Blotting , Divisão Celular/genética , Masculino , Camundongos , Dados de Sequência Molecular , Oligodesoxirribonucleotídeos , Espermatogênese/genéticaRESUMO
Signal transducers and activators of transcription (STAT) proteins are transcription factors activated by phosphorylation on tyrosine residues after cytokine stimulation. In erythropoietin receptor (EPOR)-mediated signaling, STAT5 is tyrosine-phosphorylated by EPO stimulation. Although Janus Kinase 2 (JAK2) is reported to play a crucial role in EPO-induced activation of STAT5, it is unclear whether JAK2 alone can tyrosine-phosphorylate STAT5 after EPO stimulation. Several studies indicate that STAT activation is caused by members of other families of protein tyrosine kinases such as the Src family. We previously reported that reduction of Src by induction of antisense src RNA expression suppressed EPO-promoted erythroid differentiation in K562 cells. In the present study, we explored the function of Src downstream of the EPOR-initiated signaling. Reduction of Src diminished tyrosine phosphorylation of STAT5 in K562 cells regardless of EPO treatment. The tyrosine phosphorylation level of STAT5 induced by EPO in F-36P cells was reduced in the presence of PP1 or PP2 selective Src inhibitor. In addition, the expression of dominant negative Src in F-36P cells reduced the tyrosine phosphorylation of STAT5. When Src and STAT5 were co-expressed in COS7 cells, tyrosine phosphorylation of STAT5 was observed, and tyrosine residue 694 (Tyr 694) of STAT5A was identified as the major phosphorylation site by Src. In vitro kinase assay revealed that GST-STAT5 fusion protein with the conserved C-terminal, but not the C-terminal-truncated mutant which lacks Tyr 694, was tyrosine-phosphorylated by Src. Src can thus directly tyrosine-phosphorylate the activation site of STAT5 (Tyr 694 in STAT5A), and Src may contribute to EPO-induced signal transduction via STAT5.
Assuntos
Proteínas de Ligação a DNA/metabolismo , Proteínas de Ligação a DNA/fisiologia , Eritropoetina/farmacologia , Proteínas do Leite , Fosfotirosina/metabolismo , Proteínas Proto-Oncogênicas , Transdução de Sinais , Transativadores/metabolismo , Transativadores/fisiologia , Quinases da Família src/fisiologia , Animais , Células COS , Linhagem Celular , Proteínas de Ligação a DNA/química , Ativação Enzimática , Inibidores Enzimáticos/farmacologia , Células-Tronco Hematopoéticas/metabolismo , Humanos , Janus Quinase 2 , Células K562 , Mutação , Oligorribonucleotídeos Antissenso/farmacologia , Fosforilação , Proteínas Tirosina Quinases/antagonistas & inibidores , Fator de Transcrição STAT5 , Transativadores/química , Proteínas Supressoras de Tumor , Quinases da Família src/antagonistas & inibidores , Quinases da Família src/genéticaRESUMO
In this study, we examined the effect of thrombopoietin (TPO) on the aggregation of platelets from 40 patients with myeloproliferative disorders (MPDs), including 17 patients with chronic myelogenous leukemia in the chronic phase (CML-CP), 10 with polycythemia vera, 10 with essential thrombocythemia, and three with myelofibrosis. TPO by itself dose-dependently induced the aggregation of platelets from patients with CML-CP but not from those with other MPDs or with CML-CP in cytogenetical complete remission. The expression of CD63 in CML-CP platelets was induced by TPO treatment. Phosphatidylinositol 3-kinase (PI3-kinase) was constitutively activated in CML-CP platelets. Pretreatment with PI3-kinase inhibitors (wortmannin and LY294002) dose-dependently inhibited TPO-induced aggregation of CML-CP platelets. The Abl kinase inhibitor imatinib mesylate and the Jak inhibitor AG490 suppressed TPO-induced aggregation of CML-CP platelets. Pretreatment with imatinib mesylate, but not with AG490, inhibited the activity of PI3-kinase in CML-CP platelets. In addition, tyrosine phosphorylation of Jak2 was undetected in CML-CP platelets before TPO treatment. These findings indicate that the constitutive activation of PI3-kinase primes CML-CP platelets for the aggregation induced by TPO, and that Bcr-Abl, but not Jak family protein tyrosine kinases, are involved in the constitutive activation of PI3-kinase in CML-CP platelets.
Assuntos
Plaquetas/enzimologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Agregação Plaquetária/efeitos dos fármacos , Trombopoetina/farmacologia , Androstadienos/farmacologia , Cromonas/farmacologia , Relação Dose-Resposta a Droga , Ativação Enzimática/fisiologia , Inibidores Enzimáticos/farmacologia , Humanos , Técnicas In Vitro , Morfolinas/farmacologia , Inibidores de Fosfoinositídeo-3 Quinase , Fosforilação , Agregação Plaquetária/fisiologia , Tirosina/metabolismo , WortmaninaRESUMO
We constructed a recombinant plasmid which expresses antisense src RNA after dexamethasone (Dexa) treatment, and transfected it into U937 human monoblastic leukemia cells (U937-ASRC). Induction of antisense src RNA expression diminished the amounts of c-Src and its protein tyrosine kinase (PTK) activity in U937-ASRC cells. The declines in c-Src and its PTK activity subsequently reduced the proliferation of U937-ASRC cells. To elucidate the growth signal transduction pathway downstream of c-Src, tyrosine phosphorylation of Shc was examined in U937-ASRC cells treated with Dexa. The decline in c-Src by induction of antisense src RNA expression decreased the level of tyrosine phosphorylation of Shc. Immunoprecipitated c-Src directly phosphorylated immunoprecipitated Shc on tyrosine residues in vitro. The amounts of Grb2 and Sos co-immunoprecipitated with Shc were decreased after Dexa treatment. However, the amount of Sos co-immunoprecipitated with Grb2 was apparently not affected by Dexa treatment. These results indicate that Grb2 and Sos constitutively associate with each other in U937 cells. Furthermore, the level of phosphorylation on tyrosine (204) essential for MAP kinase activation was decreased after Dexa treatment. Taken together with all these findings, it is suggested that c-Src directly phosphorylates Shc on tyrosine residues, which in turn binds to Grb2 constitutively associated with Sos to form a Shc-Grb2-Sos complex, and that the complex formation is coupled with MAP kinase activation mediated by Ras activation in U937 cells.
Assuntos
Proteínas Adaptadoras de Transdução de Sinal , Leucemia/genética , Oligopeptídeos/metabolismo , Fragmentos de Peptídeos/metabolismo , Proteínas Quinases/metabolismo , Proteínas/metabolismo , RNA Antissenso/metabolismo , Tirosina/metabolismo , Quinases da Família src/metabolismo , Linhagem Celular , Membrana Celular/metabolismo , Dexametasona , Proteína Adaptadora GRB2 , Humanos , Quinases de Proteína Quinase Ativadas por Mitógeno , Fosforilação , Plasmídeos , Transdução de Sinais , Transfecção , Quinases da Família src/genéticaRESUMO
The effects of 4-carbamoylimidazolium 5-olate (SM-108), an antipurine compound, on a human leukemia cell line, K562, were studied. Treatment with SM-108 induced erythroid differentiation of K562 cells. During a 6-day culture with 100 microM SM-108, the cell number decreased to 37% of the control number, 77% of the cells became benzidine-positive, and the hemoglobin content increased from 2.1 +/- 0.2 to 10.6 +/- 1.3 pg/cell. Cell differentiation was associated with reduction of IMP dehydrogenase activity and intracellular GTP content to 25 and 36%, respectively, of the control values within 1.5 hr. The differentiation and decrease in the GTP pool induced by SM-108 were blocked by the presence of 25 microM guanine or guanosine. SM-108 also induced erythroid differentiation of K562 subline cells transfected with pMSG (K562/pMSG), which have an additional salvage pathway for GMP production from xanthine. The addition of 100 microM xanthine prevented erythroid differentiation of this subline and restored the GTP pool. These findings suggest that the induction of erythroid differentiation of K562 cells by SM-108 may be due to an early decrease in IMP dehydrogenase activity and a subsequent decrease in GTP content in the cells. Thus, purine metabolism may have an important role in SM-108-induced differentiation.
Assuntos
Diferenciação Celular/efeitos dos fármacos , Eritrócitos/efeitos dos fármacos , Guanosina Trifosfato/metabolismo , IMP Desidrogenase/antagonistas & inibidores , Imidazóis/farmacologia , Linhagem Celular/efeitos dos fármacos , Eritrócitos/metabolismo , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva , Purinas/farmacologia , Ensaio Tumoral de Célula-Tronco , Xantina , Xantinas/farmacologiaRESUMO
Monoclonal antibodies (McAbs) against a part of v-myb gene product were prepared for the detection of human c-myb gene product (p75c-myb). Western blotting analyses with these McAbs were performed on human leukemia-lymphoma cells. All T-cell lines were positive in p75c-myb expression. B-cell lines were variable, myeloid and erythroid cells were positive although the amount of expressed p75c-myb was less than the T-cell lines. Cells isolated from patients were positive in expression except for cells from acute myeloblastic leukemia with maturation (AML M2), acute hypergranular promyelocytic leukemia (AML M3) and erythroleukemia (AML M6) developed from myelodysplastic syndromes. Differences in p75c-myb expression seemed to depend upon the differentiation stage and distinctive lineage from which each cell line had been established. The p75c-myb expression in HL60 (acute promyelocytic leukemia cell line) showed remarkably high at logarithmic growth. When examined with HL60, p75c-myb expression significantly decreased during the differentiation induced by 12-O-tetradecanoylphorbol-13-acetate or retinoic acid. These results suggest that p75c-myb expression plays a crucial role in hematopoietic cell proliferation and differentiation and that multiple mechanisms including aberrant expression of p75c-myb is involved in leukemogenesis.
Assuntos
Leucemia/metabolismo , Linfoma/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Anticorpos Monoclonais , Western Blotting , Diferenciação Celular , Divisão Celular , Feminino , Expressão Gênica , Humanos , Leucemia/genética , Leucemia/patologia , Linfoma/genética , Linfoma/patologia , Masculino , Proteínas Proto-Oncogênicas/genética , Proteínas Proto-Oncogênicas c-myb , Proto-Oncogenes , Células Tumorais Cultivadas/metabolismo , Células Tumorais Cultivadas/patologiaRESUMO
Recombinant plasmids containing v-myb' (803 bp fragment of the 3' end of v-myb) were constructed to induce sense or antisense v-myb' RNA expression with dexamethasone in human cells. These plasmids were used as a tool for the investigation of the role of c-myb gene in human leukemia cell proliferation and differentiation. They were transfected by electroporation into the K562 human leukemia cell line derived from a patient with chronic myelogenous leukemia in blastic crisis. After induction of transcription by dexamethasone, the plasmid with antisense v-myb' repressed the expression of p75c-myb from the endogenous c-myb gene of K562 cells. It also reduced the proliferation rate of K562 cells to 50% of the control level, and induced these K562 cells to express the myelomonocytic differentiation cell surface marker CD13 and increased NBT reducing activity. The plasmid with sense v-myb' did not have an effect on p75c-myb expression, the proliferation of K562 cells or the expression of myelomonocytic differentiation phenotypes. These observations suggest that antisense v-myb' RNA represses p75c-myb expression and that a decrease of p75c-myb suppresses K562 cell proliferation and induces its differentiation towards the myelomonocytic lineage.
Assuntos
Expressão Gênica , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Oncogenes , RNA Antissenso/metabolismo , Antígenos de Diferenciação Mielomonocítica/metabolismo , Crise Blástica/genética , Crise Blástica/metabolismo , Crise Blástica/patologia , Antígenos CD13 , Diferenciação Celular , Divisão Celular , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/metabolismo , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Plasmídeos , Proteínas Proto-Oncogênicas/genética , Proteínas Proto-Oncogênicas/fisiologia , Proteínas Proto-Oncogênicas c-myb , Proto-Oncogenes , Recombinação Genética , Células Tumorais Cultivadas/metabolismo , Células Tumorais Cultivadas/patologiaRESUMO
A new salvage treatment protocol consisting of VP-16, cytosine arabinoside (Ara-C), methotrexate (MTX) and L-asparaginase, known as VAMA, was administered to twelve patients with relapsed or resistant non-Hodgkin's lymphoma. All twelve patients were in advanced stage with aggressive histologic type. Four of eight patients whose tumor cells had been immunologically determined, had T-cell phenotype. Three complete and five partial responses were obtained, for an overall response rate of 67%. It is of particular interest that all four patients with T-cell phenotype responded(CR; 3 cases, PR; 1 case), and a CR duration over 31 months has been achieved in a case of T-lymphoblastic lymphoma. Severe myelosuppression was the major toxic effect, but it was generally well-tolerated with supportive therapy. These results indicate that VAMA salvage regimen can play an important role in the treatment of relapsed or resistant non-Hodgkin's lymphoma.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma não Hodgkin/tratamento farmacológico , Adulto , Asparaginase/administração & dosagem , Citarabina/administração & dosagem , Resistência a Medicamentos , Feminino , Humanos , Linfoma não Hodgkin/patologia , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Podofilotoxina/administração & dosagem , Indução de RemissãoRESUMO
Seven patients with essential thrombocythemia and two patients with polycythemia vera were treated with ranimustine (MCNU). MCNU was given intravenously by drip infusion at a dose of 40-80 mg/m2 with intervals arranged in terns of the counts of both white blood cell and platelets. All cases with essential thrombocythemia obtained complete response, but the cases with polycythemia vera needed the combination of phlebotomy. The therapeutic effects were maintained for 2-5 months. No serious side effect was recognized except in two cases (22%) of mild nausea. Our study indicates that MCNU is useful for chemotherapy of chronic myeloproliferative disorders, especially, essential thrombocythemia.
Assuntos
Compostos de Nitrosoureia/uso terapêutico , Policitemia Vera/tratamento farmacológico , Trombocitemia Essencial/tratamento farmacológico , Adulto , Idoso , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Compostos de Nitrosoureia/administração & dosagem , Contagem de Plaquetas , Policitemia Vera/sangue , Trombocitemia Essencial/sangueRESUMO
OBJECTIVE: The aim of this study was to assess the feasibility of ultrashort echo time (UTE) imaging in the visualization of middle ear ossicles in normal subjects. METHODS: 12 young adult volunteers (males/females = 6/6, age 25-44 years, mean 30.3 years) with normal hearing levels underwent MRI studies using a 3.0 T clinical unit with an eight-channel SENSE head coil. For each subject, the whole head was imaged using a three-dimensional dual-echo UTE imaging sequence with radial trajectory and the following parameters: field of view, 240 × 240 × 240 mm; matrix, 320 × 320; flip angle, 7°; repetition time/echo time (TE)1/TE2, 8.0 ms/0.14 ms/1.8 ms; acquisition voxel size, 0.75 × 0.75 × 0.75 mm; number of signals averaged, 1; imaging time, 27 min 20 s. Subsequently, subtraction images were obtained by subtracting long TE (1.8 ms) images from short TE (0.14 ms) images. By using these three images, the visibility of the bilateral middle ear ossicles was evaluated. Moreover, as a reference for the UTE findings, CT images of the temporal bone were obtained in one volunteer. RESULTS: In all subjects, the middle ear ossicles were clearly visualized as a high signal intensity spot surrounded by a signal void of air on short TE images bilaterally, while they were not visible in long TE images in any of the subjects. The subtraction images provided better contrast of the ossicles. CONCLUSION: We demonstrated the feasibility of UTE imaging of the middle ear ossicle in normal subjects.
Assuntos
Ossículos da Orelha/anatomia & histologia , Imagem Ecoplanar/métodos , Adulto , Ossículos da Orelha/diagnóstico por imagem , Estudos de Viabilidade , Feminino , Humanos , Processamento de Imagem Assistida por Computador/métodos , Imageamento Tridimensional/métodos , Imageamento por Ressonância Magnética/métodos , Masculino , Estudos Prospectivos , Técnica de Subtração , Osso Temporal/diagnóstico por imagem , Tomografia Computadorizada por Raios X/métodosRESUMO
BACKGROUND AND PURPOSE: MSDE preparation is a technique for black-blood imaging. Our purpose was to evaluate the usefulness of a 3D TSE sequence with MSDE preparation in detecting brain metastases by comparing it with conventional sequences. MATERIALS AND METHODS: Postcontrast images of 227 patients who were suspected of having brain metastasis were prospectively obtained by using 3 T1-weighted 3D sequences: a gradient-echo sequence (MPRAGE), TSE-noMSDE, and TSE-MSDE. The number of visualized blood vessels and the lesion-to-normal CNR were compared among the 3 sequences. An observer test involving 9 radiologists was performed, and their diagnostic performance by using TSE-MSDE, MPRAGE, and combined TSE-MSDE and MPRAGE was compared by means of an FOM as an index of diagnostic performance derived by the JAFROC analysis, sensitivity, FP/case, and reading time. RESULTS: TSE-MSDE resulted in significantly better vessel suppression than the other 2 methods. TSE with and without MSDE resulted in significantly higher CNRs than MPRAGE. In the observer test, significantly higher sensitivity and FOM as well as significantly shorter reading time were achieved by TSE-MSDE compared with MPRAGE, but FP/case was significantly higher with TSE-MSDE. Combined TSE-MSDE/MPRAGE resulted in significantly higher sensitivity and FOM and similar FP/case and reading time compared with MPRAGE alone. CONCLUSIONS: With blood vessel suppression and increased CNR, TSE-MSDE improves radiologists' performances in detecting brain metastases compared with MPRAGE, but it may increase FP results. Combined with MPRAGE, TSE-MSDE achieves high diagnostic performance while maintaining a low FP rate.
Assuntos
Neoplasias Encefálicas/secundário , Imagem Ecoplanar/métodos , Imagem Ecoplanar/normas , Neoplasias Pulmonares/patologia , Neurorradiografia/normas , Adulto , Idoso , Idoso de 80 Anos ou mais , Artefatos , Neoplasias da Mama/patologia , Artérias Cerebrais/anatomia & histologia , Bases de Dados Factuais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Bucais/patologia , Neurorradiografia/estatística & dados numéricos , Variações Dependentes do Observador , Neoplasias Pancreáticas/patologia , Estudos Prospectivos , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
BACKGROUND AND PURPOSE: Previous reports have shown that DWI is useful in detecting cholesteatoma. SS-EPI is the most widely used DWI technique. However, SS-EPI may have susceptibility artifacts due to field inhomogeneity in the imaging of the temporal bone region. Our purpose was to prospectively evaluate the advantage of MS-EPI for the diagnosis of middle ear cholesteatoma by comparing it with SS-EPI. MATERIALS AND METHODS: We studied 29 patients with preoperatively suspected acquired cholesteatoma. Each patient underwent an MR imaging examination including both SS-EPI and MS-EPI by using a 1.5T MR imaging scanner. Images of the 29 patients (58 temporal bones including 30 with and 28 without cholesteatoma) were reviewed by 2 independent neuroradiologists. The confidence level for the presence of cholesteatoma was graded on a scale of 0-2 (0 = none, 1 = equivocal, 2 = definite). Interobserver agreement as well as sensitivity, specificity, and accuracy were assessed for the 2 readers. RESULTS: Excellent interobserver agreement was shown for both MS-EPI (κ = 0.856) and SS-EPI (κ = 0.820). MS-EPI was associated with higher sensitivity (76.7%) and accuracy (87.9%) than SS-EPI (sensitivity = 50.0%, accuracy = 74.1%) (P < .05), while both methods showed 100% specificity. CONCLUSIONS: Compared with SS-EPI, MS-EPI improves the accuracy of the diagnosis of acquired middle ear cholesteatomas.
Assuntos
Colesteatoma da Orelha Média/diagnóstico , Imagem de Difusão por Ressonância Magnética/métodos , Imagem Ecoplanar/métodos , Aumento da Imagem/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Adulto JovemRESUMO
Imaging has been increasingly recognized as a powerful tool for diagnosing Alzheimer's disease (AD). Magnetic resonance imaging (MRI) is advantageous over other imaging modalities due to its non-invasiveness and multi-parametric capabilities. In addition to the morphological assessment, several new MR imaging approaches have shown potential for improved AD diagnosis. This paper focuses on two of these advanced MRI-based approaches: diffusion-weighted imaging and arterial spin labeling.